CAR

Prime Therapeutics and Magellan Rx to present three managed care pharmacy research studies at AMCP Nexus

Retrieved on: 
Monday, October 16, 2023

EAGAN, Minn., Oct. 16, 2023 /PRNewswire/ -- Prime Therapeutics LLC/Magellan Rx Management (Prime/MRx) will present three research studies at the 2023 Academy of Managed Care Pharmacy (AMCP) Nexus event, October 16-19 in Orlando, Fla.

Key Points: 
  • EAGAN, Minn., Oct. 16, 2023 /PRNewswire/ -- Prime Therapeutics LLC / Magellan Rx Management (Prime/MRx) will present three research studies at the 2023 Academy of Managed Care Pharmacy (AMCP) Nexus event , October 16-19 in Orlando, Fla.
    Health outcomes teams from the organization used integrated medical and pharmacy claims data to evaluate real-world drug utilization, managed care pharmacy programs, and associated costs of care for a range of conditions, including diabetes, lymphoma, and hemophilia.
  • This study illustrates the impact of comprehensive hemophilia care and managed care strategies which led to more than $3.7 million in cost avoidance.
  • More information about these presentations can be found on Prime Therapeutics' events page or the AMCP Nexus website .
  • And for further insights on the studies noted above, visit Prime Therapeutics' newsroom .

Allogeneic CAR Cell Therapy Market Surges in Response to Advancements in Gene Editing and IP Trends - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 5, 2023

The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.

Key Points: 
  • The global allogeneic chimeric antigen receptor (CAR) cell therapy market is experiencing rapid growth, driven by intellectual property (IP) trends, advancements in gene editing tools, and emerging players entering the field.
  • IP Trends Fuel Growth: The analysis of patent publications reveals that interest in allogeneic CAR therapies began in the late 2000s.
  • Advantages of Allogeneic CAR: Allogeneic CAR therapies offer several advantages over autologous CAR therapies, including faster production (10-11 days vs. over three weeks), scalability, standardization, and reduced manufacturing costs.
  • The report profiles key players in the allogeneic CAR cell therapy market, offering insights into their patent portfolios, geographical coverage, IP trends, and clinical trials.

Kyverna Therapeutics Announces FDA Clearance of IND for KYV-101, a Novel Fully Human CD19 CAR T-Cell Therapy to Treat Scleroderma

Retrieved on: 
Wednesday, October 11, 2023

EMERYVILLE, Calif., Oct. 11, 2023 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a clinical-stage cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the clearance of the third Investigational New Drug (IND) application for KYV-101 by the U.S. Food and Drug Administration (FDA). This will allow Kyverna to initiate a Phase 1/2 open-label, multicenter study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).

Key Points: 
  • This will allow Kyverna to initiate a Phase 1/2 open-label, multicenter study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T cell therapy for the treatment of diffuse cutaneous systemic sclerosis (scleroderma).
  • "We welcome Kyverna's enthusiasm and interest to push forward with their CAR T approach in scleroderma patients with the KYSA-5 trial," said Luke Evnin, chairman of the Scleroderma Research Foundation.
  • "We are immensely proud of being able to bring KYV-101 to patients suffering from scleroderma," said Peter Maag, Ph.D., chief executive officer of Kyverna Therapeutics.
  • "We are keen to initiate our KYSA-5 trial in this new patient population and generate data to support our KYV-101 design goals.

Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology

Retrieved on: 
Wednesday, October 11, 2023

WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells. This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.

Key Points: 
  • WEXFORD, Pa., Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that it has expanded its exclusive license agreement with the University of Pittsburgh to include the SNAP-CAR technology platform in natural killer (NK) cells.
  • This amended agreement builds upon the original exclusive license agreement with the University of Pittsburgh for SNAP-CAR T-Cell, a "universal" CAR T technology platform designed to target multiple antigens simultaneously and potentially address a range of hematologic and solid tumors, including HER2-expressing cancer.
  • The addition of SNAP-CAR NK adds a third NK-focused technology to Coeptis' development portfolio.
  • "Expanding this agreement to include allogeneic NK cells enables our teams to develop cell therapies that can be developed with off-the-shelf convenience and greater access to patients.

Financial Results For The Nine Months Ended 30 September 2023

Retrieved on: 
Tuesday, October 10, 2023

DOHA, Qatar, Oct. 10, 2023 /PRNewswire/ -- QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the nine months ended 30 September 2023.

Key Points: 
  • DOHA, Qatar, Oct. 10, 2023 /PRNewswire/ -- QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the nine months ended 30 September 2023.
  • Net profit for the nine months ended 30 September 2023 reached QAR11.9 billion (USD3.3 billion), an increase of 8% compared to same period last year.
  • Also QNB Group's loans to deposits ratio remained strong at 99.2% as at 30 September 2023, well within the regulatory limits.
  • Also, Liquidity Coverage Ratio (LCR) and Net Stable Funding Ratio (NSFR) as at 30 September 2023 amounted to 166% and 102% respectively.

Financial Results For The Nine Months Ended 30 September 2023

Retrieved on: 
Tuesday, October 10, 2023

DOHA, Qatar, Oct. 10, 2023 /PRNewswire/ -- QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the nine months ended 30 September 2023.

Key Points: 
  • DOHA, Qatar, Oct. 10, 2023 /PRNewswire/ -- QNB Group, the largest financial institution in the Middle East and Africa (MEA) region, announced its results for the nine months ended 30 September 2023.
  • Net profit for the nine months ended 30 September 2023 reached QAR11.9 billion (USD3.3 billion), an increase of 8% compared to same period last year.
  • Also QNB Group's loans to deposits ratio remained strong at 99.2% as at 30 September 2023, well within the regulatory limits.
  • Also, Liquidity Coverage Ratio (LCR) and Net Stable Funding Ratio (NSFR) as at 30 September 2023 amounted to 166% and 102% respectively.

Regen BioPharma, Inc. Receives First Phase of Confirmatory Study

Retrieved on: 
Tuesday, October 10, 2023

SAN DIEGO, Oct. 10, 2023 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic (https://www.prnewswire.com/news-releases/regen-biopharma-inc--begins-exp...) while also identifying new, unexpected and potentially extremely useful findings in developing cell therapy treatments for autoimmune disorders https://www.prnewswire.com/news-releases/studies-on-regen-biopharma-incs....

Key Points: 
  • The company has now received the first set of confirmatory data which demonstrates that T cells which express the chimeric antigen receptor (CAR) construct targeting CD19 and expressing siRNA for NR2F6 were  successfully created.
  • In addition, the siRNA that is designed into the CAR T-cell was very highly expressed.
  • Subsequent studies will determine if the expression of NR2F6 mRNA is suppressed or enhanced as a result of the high expression of siRNA.
  • If it is inhibited, we will focus on using these DuraCAR cells as originally envisioned - to attack solid tumors.

ImmPACT Bio Granted FDA Fast Track Designation for IMPT-514 for the Treatment of Both Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus

Retrieved on: 
Tuesday, October 10, 2023

LOS ANGELES, Oct. 10, 2023 /PRNewswire/ -- ImmPACT Bio USA, Inc. ("ImmPACT Bio"), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for IMPT-514, a potential first-in-class CD19/CD20 CAR-T therapy for the treatment of patients with active refractory lupus nephritis (LN) and systemic lupus erythematosus (SLE). In August 2023, ImmPACT Bio received FDA clearance to initiate clinical development of IMPT-514 in an open label Phase 1b/2 dose escalation trial in participants with active, refractory SLE.

Key Points: 
  • In August 2023, ImmPACT Bio received FDA clearance to initiate clinical development of IMPT-514 in an open label Phase 1b/2 dose escalation trial in participants with active, refractory SLE.
  • "SLE is a systemic, chronic, multi-organ autoimmune disease associated with increased risk of mortality, progressive organ damage, and reduced health-related quality of life.
  • "To address these limitations, IMPT-514 was designed as a one-time treatment option with potential to reset the immune system through deep B-cell depletion.
  • We look forward to dosing the first patient in our Phase 1b/2 trial for the treatment of active, refractory SLE expected in early 2024."

dPCR, qPCR and RT-qPCR: Advantages and Challenges in Pre-clinical and Clinical Development, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, October 4, 2023

TORONTO, Oct. 4, 2023 /PRNewswire-PRWeb/ -- Regulated digital polymerase chain reaction (dPCR), quantitative polymerase chain reaction (qPCR) and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) are extensively utilized to support biodistribution, vector shedding, gene expression, chimeric antigen receptor (CAR) T cell therapy and oncolytic viral bioanalytical studies.

Key Points: 
  • In this free webinar, learn about the advantages and disadvantages of dPCR, qPCR and RT-qPCR.
  • The featured speakers will discuss the best practices and strategies for optimizing dPCR, qPCR and RT-qPCR assays in vaccine and biotherapeutic research.
  • Attendees will learn the relevant recommendations related to dPCR / qPCR / RT-qPCR in pre-clinical and clinical settings.
  • In this presentation, the featured speakers will review the advantages and disadvantages of dPCR, qPCR and RT-qPCR as it relates to vaccine and biotherapeutic research.

Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023

WEXFORD, Pa. , Oct. 4, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that an abstract involving SNAP-CAR has been accepted for presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023).  SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.

Key Points: 
  • Poster to be presented by research team from University of Pittsburgh, led by Jason Lohmueller, Ph.D., Assistant Professor of Immunology
    WEXFORD, Pa. , Oct. 4, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that an abstract involving SNAP-CAR has been accepted for presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023).
  • SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego.
  • The poster presentation titled, "SNAP CAR T cells for programmable antigen targeting," will detail research involving SNAP-CAR, a "universal" CAR T cell therapy platform that can be adapted to different cancer indications.
  • "SNAP-CAR represents a powerful technology with the potential to be engineered to address numerous cancers, including HER2-expressing cancer, which we are targeting as our potential first-in-human clinical development program."